19
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Evaluación positiva de medicamentos: julio, septiembre y octubre de 2022 Translated title: Positive assessment of drugs: July, September and October of 2022

      brief-report
      , , ,
      Sanidad Militar
      Ministerio de Defensa
      Abaloparatida (Eladynos®), Espesolimab (Spevigo®), Faricimab (Vabysmo®), Fosdenopterina (Nulibry®), Gozetotida (Locametz®), Loncastuximab tesirina (Zynlonta®), Maralixibat (Livmarli®), Maribavir (Livtencity®), Mitapivat (Pyrukynd®), Nirsevibab (Beyforuts®), Nivolumab/Relatlimab (Opdualag®), Sutimlimab (Enjaymo®), Tabelecleucel (Ebvallo®), Teclistamab (Tecvayli®), Tezepelumab (Tezspire®), Tirzepatida (Mounjaro®), Vacuna tetravalente contra el dengue (Qdenga ®), Vipivotida tetraxetan lutecio (177LU) (Pluvicto®), Voclosporina (Lupkynis®), Vutrisiran (Amvuttra ®), Abaloparatida (Eladynos®), Espesolimab (Spevigo®), Faricimab (Vabysmo®), Fosdenopterina (Nulibry®), Gozetotida (Locametz®), Loncastuximab tesirina (Zynlonta®), Maralixibat (Livmarli®), Maribavir (Livtencity®), Mitapivat (Pyrukynd®), Nirsevibab (Beyforuts®), Nivolumab/Relatlimab (Opdualag®), Sutimlimab (Enjaymo®), Tabelecleucel (Ebvallo®), Teclistamab (Tecvayli®), Tezepelumab (Tezspire®), Tirzepatida (Mounjaro®), Vacuna tetravalente contra el dengue (Qdenga®), Vipivotida tetraxetan lutecio (177LU) (Pluvicto®), Voclosporina (Lupkynis®), Vutrisiran (Amvuttra®)

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          RESUMEN Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Europea del Medicamento, hechos públicos en julio, septiembre y octubre de 2022 y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento.

          Translated abstract

          SUMMARY: The drugs assessed by the European Medicines Agency made public in July, September and October of 2022, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

          Related collections

          Most cited references43

          • Record: found
          • Abstract: found
          • Article: not found

          Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

          Despite advancements in care, many people with type 2 diabetes do not meet treatment goals; thus, development of new therapies is needed. We aimed to assess efficacy, safety, and tolerability of novel dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist tirzepatide monotherapy versus placebo in people with type 2 diabetes inadequately controlled by diet and exercise alone.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants

            Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extended half-life. The efficacy and safety of nirsevimab in healthy late-preterm and term infants are uncertain.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

              Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exists for prevention of RSV in healthy infants. Nirsevimab is a monoclonal antibody with an extended half-life that is being developed to protect infants for an entire RSV season with a single intramuscular dose.
                Bookmark

                Author and article information

                Journal
                sm
                Sanidad Militar
                Sanid. Mil.
                Ministerio de Defensa (Madrid, Madrid, Spain )
                1887-8571
                December 2022
                : 78
                : 4
                : 261-267
                Affiliations
                [4] Madrid orgnameHospital Central de la Defensa Gómez Ulla orgdiv1Servicio de Farmacia Hospitalaria España
                [1] Madrid orgnameHospital Central de la Defensa Gómez Ulla orgdiv1Servicio de Farmacología Clínica España
                [3] Madrid orgnameHospital Central de la Defensa Gómez Ulla orgdiv1Servicio de Farmacia Hospitalaria España
                [2] Madrid orgnameHospital Central de la Defensa Gómez Ulla orgdiv1Servicio de Farmacología Clínica España
                Article
                S1887-85712022000400010 S1887-8571(22)07800400010
                10.4321/s1887-857120220004000010
                10b41803-b769-4a50-b064-3b2dfbdb91b9

                http://creativecommons.org/licenses/by/4.0/

                History
                : 02 December 2022
                : 09 December 2022
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 49, Pages: 7
                Product

                SciELO Spain

                Categories
                Nota Técnica

                Gozetotida (Locametz®),Loncastuximab tesirina (Zynlonta®),Maralixibat (Livmarli®),Maribavir (Livtencity®),Mitapivat (Pyrukynd®),Nirsevibab (Beyforuts®),Nivolumab/Relatlimab (Opdualag®),Voclosporina (Lupkynis®),Vipivotida tetraxetan lutecio (177LU) (Pluvicto®),Vacuna tetravalente contra el dengue (Qdenga®),Tirzepatida (Mounjaro®),Tezepelumab (Tezspire®),Vutrisiran (Amvuttra®),Teclistamab (Tecvayli®),Tabelecleucel (Ebvallo®),Sutimlimab (Enjaymo®),Fosdenopterina (Nulibry®),Faricimab (Vabysmo®),Espesolimab (Spevigo®),Abaloparatida (Eladynos®),Vutrisiran (Amvuttra ®),Vacuna tetravalente contra el dengue (Qdenga ®)

                Comments

                Comment on this article